vTv Therapeutics
VTVT
35 hedge funds and large institutions have $59M invested in vTv Therapeutics in 2026 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 3 closing their positions.
300% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 3
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
30% more funds holding
Funds holding: 27 → 35 (+8)
15% more capital invested
Capital invested by funds: $51.3M → $59M (+$7.65M)
5.17% more ownership
Funds ownership: 32.6% → 37.76% (+5.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$7.49M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$486K |
| 3 |
State Street
Boston,
Massachusetts
|
+$387K |
| 4 |
Goldman Sachs
New York
|
+$284K |
| 5 |
BHCM
Brevan Howard Capital Management
St. Helier,
Jersey
|
+$273K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TECP
Trails Edge Capital Partners
Atlanta,
Georgia
|
-$3.32M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$307K |
| 3 |
6CM
683 Capital Management
New York
|
-$82.3K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$50.7K |
| 5 |
Citigroup
New York
|
-$9.76K |
VTVT Hedge Fund Activity: Q1 2026 in Review
35 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q1 2026, worth a combined $59M — up 15% from $51.3M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new VTVT positions and 3 closed out — a net gain of 9 holders — while 7 added to existing stakes and 4 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $7.49M. The largest seller was Trails Edge Capital Partners, cutting an estimated $3.32M.
- 35 institutional investors held vTv Therapeutics (VTVT) as of Q1 2026, up from 27 in Q4 2025.
- Funds reported $59M of vTv Therapeutics stock for Q1 2026, up 15% quarter-over-quarter.
- 12 funds opened new vTv Therapeutics positions in Q1 2026 and 3 closed out, a net change of +9 holders.
- The largest vTv Therapeutics buyer in Q1 2026 was Millennium Management, an estimated $7.49M added.
- The largest vTv Therapeutics seller in Q1 2026 was Trails Edge Capital Partners, an estimated $3.32M sold.
Based on aggregated 13F filings for Q1 2026.